Meet the Team
behind Tubulis

Christian Grøndahl, Dr. Med, DVM, PhD, MBA, serves as the Chairman of the Board.

Christian founded or co-founded multiple biotechnology companies exploring novel technology platforms including SNIPR Biome, Freeline Therapeutics, Gyroscope Therapeutics, Quadrucept Bio and Folium Food Science. Since 2015, he has held the position of Co-founder and CEO of SNIPR Biome. Prior, he served as the CEO of Kymab as well as the CSO and Head of R&D at Zealand Pharma. He also worked in R&D and held various corporate development roles at Novo Nordisk.

Christian studied Veterinary Medicine and obtained his PhD and MD degrees at the University of Copenhagen, Denmark. In 2007 he received his MBA from the University of Lausanne, Switzerland.

Caroline Goddeeris, PhD, serves as a Board Member at Tubulis.

Caroline is a Venture Partner at Fund+, focused on VC investments in Life Sciences. She is a board member in several biotechs including TargED Biopharmaceuticals, Astrivax, and Confo Therapeutics while also serving on the board of SFPIM, Belgium’s Sovereign Wealth Fund. Caroline previously worked at Gimv where she was responsible for driving investments in several medtech and biotech companies including Onward (formerly G-Therapeutics) and Topas Therapeutics. She also served on the boards of Complix and Multiplicom (sold to Agilent). Caroline started her career at UCB taking on various subsequent roles ranging from marketing and sales to business development, portfolio valuation and strategy, and finally commercial lead for their immunology portfolio.

Caroline holds a Ph.D. in Pharmaceutical Sciences from KU Leuven followed by an MBA and an executive master’s in corporate finance, both from Vlerick Business School.

Sofia Ioannidou, PhD, is a Board Member at Tubulis.

Sofia is a Partner in the Life Sciences Team of Andera Partners (formerly Edmond de Rothschild Investment Partners), which she joined in 2009. She also holds Board seats at several biotech companies, including Tricares, Avalyn and Exciva. Prior to Andera, she worked as a consultant at the Life Sciences team of L.E.K. Consulting London and as a research scientist at Eyetech Pharmaceuticals in Boston.

Sofia studied Biochemistry at the University of Oxford and holds a PhD in Cell Biology from University College London.

Christoph Broja serves as a Board Member at Tubulis.

Christoph Broja is a Managing Director at EQT Life Sciences and an experienced investment professional with expertise in Healthcare/Life Sciences investments. He has held Board positions at several private biotech companies, including Germany-based Cardior Pharmaceuticals. Before joining EQT Life Sciences, he was a Principal in the investment team at Boston-based Gurnet Point Capital, where he was involved in several investments in biopharma, medical devices, and molecular diagnostics.

Christoph holds a degree in Business Administration and is a CFA Charterholder.

Valentin Piëch, PhD, is a Board Member at Tubulis.

Valentin is a Partner at BioMedPartners with a strong background in venture capital, science and technology. He also serves as Managing Director at VP Venture Partners, a life sciences-focused VC firm he founded in 2020. Valentin also founded impact2partners, a private VC company with a focus on companies in the rare disease space. Previously, he was an Investment Analyst and then Principal at Nextech Invest, a VC firm focusing on oncology. In addition, he is a private investor in several start-up and growth companies.

Valentin holds a PhD in Neuroscience from the Rockefeller University, a Master’s degree in Cognitive and Neural Systems from Boston University and a Master’s degree in Mechanical and Process Engineering from the Federal Institute of Technology in Zurich (ETH).

Kanishka Pothula serves as a Board Member at Tubulis.

Kanishka is a partner at Nextech Ventures (US) and the head of its Public Markets effort. Prior to joining Nextech Ventures, Kanishka worked for almost 11 years with BVF Partners – a premier biotechnology-focused hedge fund. During his tenure at BVF, Kanishka helped manage the growth of the fund from several hundred million to several billion under management. Before BVF, Kanishka was an Associate at BroadOak Capital Partners and worked as a Research Associate at the Moore’s Cancer Center at the University of California, San Diego’s Medical School.

Kanishka holds a M.S. in Biotechnology from Georgetown University and a B.S. in Bioengineering from the University of California, San Diego. He serves as a board observer to Flare Therapeutics.

Debasish Roychowdhury, MD, is a Board Member at Tubulis.

Debasish is a medical oncologist/hematologist and a proven leader in the pharmaceutical and biotech industry with many years of patient care, academic research and teaching experience. He is the co-founder and CTO of Partner Therapeutics, a commercial biotech based in Lexington, MA. Debasish has served as the CMO at Seragon and Ra Pharmaceuticals and served as a consultant for other biotech companies and academic centers.
Prior to Seragon, Debasish served as the Senior Vice President and Head of the Global Oncology Division at Sanofi, the Vice President for Clinical Development at GlaxoSmithKline, and directed the Oncology global regulatory group at Eli Lilly and Company. Prior to his role in industry, he served as faculty member at the University of Cincinnati.

Debasish is a member of the Board of Directors for ImCheck Therapeutics, T-knife Biotechnology, Rgenta Therapeutics, Monopteros Therapeutics and Fund+ and serves on multiple scientific advisory boards. He is on the faculty of the Department of Biological Engineering, MIT, Cambridge.

Debasish trained at the All India Institute of Medical Sciences and University of California, San Francisco.

Dominik Schumacher, PhD, serves as the Chief Executive Officer of Tubulis.

From the early founding phase on, Dominik successfully secured several prestigious start-up awards for Tubulis. In 2019, he was awarded as one of MIT’s Innovators Under 35. Dominik is also a Life Science Investor and has been actively investing in young, European biotech companies. Prior to co-founding Tubulis in 2018, Dominik worked at the Leibniz-Forschungsinstitut für Molekulare Pharmacology (FMP) and as a group leader at the Ludwig Maximillian University (LMU) in Munich.

Dominik obtained his PhD from the Humboldt University of Berlin, Germany and studied Chemistry and Economics at the Heinrich Heine University in Dusseldorf